News

  • 1st Czechoslovak Congress of Medical Genetics 2025

    In the spring, we will participate in the 1st Czechoslovak Congress of Medical Genetics, which will take place from April 2–4, 2025, at the Cultural and Congress Center Elektra in the spa town of Luha...

    Read more
  • RANK 2025

    Visit us at the 19th edition of the RANK 2025 conference, which will take place on March 19th and 20th at the Zlatá Štika Hotel in Pardubice. The conference is organized by the Czech Society of Clinic...

    Read more
  • Kapras Day 2025

    We would like to invite you to the 23rd Kapras Day on the topic of  "Clinical Genetics," which will take place on Wednesday, February 26, 2025, in the Congress Hall of Hotel Olšanka in Prague. We loo...

    Read more
Show news archive
https://www.carolinabiosystems.cz/1258-thickbox_default/kras-nras-mutations-detection-kit.jpg View full size

KRAS/NRAS Mutations Detection Kit

Contact us

8.01.0179

CE-IVDD

24 tests per kit

up to 1% sensitivity

Detection of 19 KRAS mutations (exons 2, 3 and 4) and 13 NRAS mutations (exons 2, 3 and 4)

RAS protein is a GTPase and one of the key molecules in the downstream signaling pathway of epidermal growth factor receptor (EGFR). These pathways control cell proliferation, differentiation and apoptosis. Frequency of KRAS and NRAS mutations in colorectal cancer are 36~40% and 1~6% respectively. Most frequent mutations are in exons 2, 3 and 4. RAS mutation is predictive of a very poor response to cetuximab (Erbitux®) and panitumumab (Vectibix®) therapy in colorectal cancer (CRC).[1] The most reliable way to predict whether a colorectal cancer patient will respond to one of the EGFR-inhibiting drugs is to test for activating mutations in the RAS gene.

Cart  

No products

0,00 € Total

Cart Checkout

Payment gate

Platební loga